Hematologic toxicity of immunosuppressive treatment

Area of Science:

• Pharmacology
• Hematology
• Transplantation Medicine

Background:

• Immunosuppressive agents are crucial for preventing organ transplant rejection.
• Hematologic toxicities, including anemia, leukopenia, and thrombocytopenia, are known side effects.
• These toxicities can arise from bone marrow suppression or hemolysis.

Purpose of the Study:

• To summarize the hematologic toxicities associated with immunosuppressive agents.
• To identify specific agents linked to bone marrow suppression and hemolytic complications.
• To highlight factors that may exacerbate these adverse effects.

Main Methods:

• Review of literature on immunosuppressive agent-induced hematologic toxicity.
• Analysis of drug classes and their associated hematologic adverse events.
• Identification of co-administered drugs and infections that potentiate toxicity.

Main Results:

• Azathioprine and mycophenolate mofetil are frequently associated with bone marrow suppression.
• Cyclosporine, tacrolimus, and muromonab (OKT3) can cause hemolytic-uremic syndrome, potentially leading to allograft loss.
• Tacrolimus and cyclosporine can rarely cause microangiopathic hemolytic anemia and thrombocytopenia due to red blood cell destruction in small blood vessels.
• Viral infections (e.g., cytomegalovirus), ganciclovir, ACE inhibitors, ARBs, sulfamethoxazole/trimethoprim, and allopurinol can worsen bone marrow suppression, especially with purine biosynthesis inhibitors like azathioprine and mycophenolate mofetil.

Conclusions:

• Hematologic toxicity is a significant concern with immunosuppressive therapy.
• Understanding drug-specific risks and potentiating factors is vital for patient management.
• Close monitoring for hematologic adverse events is essential in immunosuppressed patients, particularly transplant recipients.